These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 31080133)

  • 21. Conference report: International Haemovigilance Seminar and the SHOT Annual Symposium, 10-12 July 2018.
    Bolton-Maggs PHB
    Transfus Med; 2019 Aug; 29(4):247-252. PubMed ID: 30592099
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Transfusion-associated hazards: A revisit of their presentation.
    Garraud O; Sut C; Haddad A; Tariket S; Aloui C; Laradi S; Hamzeh-Cognasse H; Bourlet T; Zeni F; Aubron C; Ozier Y; Laperche S; Peyrard T; Buffet P; Guyotat D; Tavernier E; Cognasse F; Pozzetto B; Andreu G
    Transfus Clin Biol; 2018 May; 25(2):118-135. PubMed ID: 29625790
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Blood transfusion and blood products: indications, complications. Haemovigilance].
    Laget L; Chiaroni J; Pirenne F
    Rev Prat; 2020 May; 70(5):e167-e174. PubMed ID: 33058657
    [No Abstract]   [Full Text] [Related]  

  • 24. Acute blood transfusion reactions in a tertiary care hospital in Pakistan - an initiative towards haemovigilance.
    Borhany M; Anwar N; Tariq H; Fatima N; Arshad A; Naseer I; Shamsi T
    Transfus Med; 2019 Aug; 29(4):275-278. PubMed ID: 29845667
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Evolving Role of Information Technology in Haemovigilance Systems.
    Ramoa A; Condeço J; Escoval MA; Faber JC; Fdez-Riverola F; Lourenço A
    J Healthc Eng; 2018; 2018():6183468. PubMed ID: 29707185
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Quality validation of data in national haemovigilance systems in Europe: report of a survey on current state of practice.
    Wiersum-Osselton JC; Faber JC; Politis C; Brand A; van der Bom JG; Schipperus MR
    Vox Sang; 2013 Apr; 104(3):214-7. PubMed ID: 23061879
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pulmonary complications of transfusion: Changes, challenges, and future directions.
    Grey S; Bolton-Maggs P
    Transfus Med; 2020 Dec; 30(6):442-449. PubMed ID: 32924216
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safer blood transfusion.
    BROWN IW
    Blood; 1953 Feb; 8(2):182-6. PubMed ID: 13018353
    [No Abstract]   [Full Text] [Related]  

  • 29. Development of standard definitions for surveillance of complications related to blood donation.
    Goldman M; Land K; Robillard P; Wiersum-Osselton J
    Vox Sang; 2016 Feb; 110(2):185-8. PubMed ID: 26361365
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hemovigilance drives improved transfusion safety.
    Murphy MF
    Transfusion; 2021 Apr; 61(4):1333-1335. PubMed ID: 33831223
    [No Abstract]   [Full Text] [Related]  

  • 31. Direct costs of transfusion reactions - an expert judgement approach.
    Janssen MP; van Tilborgh AJW; de Vooght KMK; Bokhorst AG; Wiersum-Osselton JC
    Vox Sang; 2018 Feb; 113(2):143-151. PubMed ID: 29124766
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The French haemovigilance system.
    Noel L; Debeir J; Cosson A
    Vox Sang; 1998; 74 Suppl 2():441-5. PubMed ID: 9704479
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Hospital haemovigilance and adverse events or reactions: who notifies and what?].
    Gouëzec H; Bazin A; Lassale B; Huchet C; Artéro N
    Transfus Clin Biol; 2012 Nov; 19(4-5):178-81. PubMed ID: 23043856
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Transfusion-associated circulatory overload in Ireland: a review of cases reported to the National Haemovigilance Office 2000 to 2010.
    Piccin A; Cronin M; Brady R; Sweeney J; Marcheselli L; Lawlor E
    Transfusion; 2015 Jun; 55(6):1223-30. PubMed ID: 25522667
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Public policy, blood safety and haemovigilance.
    Roberts DJ
    Transfus Med; 2011 Dec; 21(6):357-8. PubMed ID: 22082175
    [No Abstract]   [Full Text] [Related]  

  • 36. [French haemovigilance from 1994 to nowadays: Evolution and prospects].
    Lassale B; Daurat G; Besse-Moreau M; Aullen JP
    Transfus Clin Biol; 2017 Sep; 24(3):268-272. PubMed ID: 28647104
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Online reporting system for transfusion-related adverse events to enhance recipient haemovigilance in Japan: a pilot study.
    Odaka C; Kato H; Otsubo H; Takamoto S; Okada Y; Taneichi M; Okuma K; Sagawa K; Hoshi Y; Tasaki T; Fujii Y; Yonemura Y; Iwao N; Tanaka A; Okazaki H; Momose SY; Kitazawa J; Mori H; Matsushita A; Nomura H; Yasoshima H; Ohkusa Y; Yamaguchi K; Hamaguchi I
    Transfus Apher Sci; 2013 Feb; 48(1):95-102. PubMed ID: 22954634
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Haemovigilance in the health care establishment: its role in pediatric transfusion].
    Weiller J; Delbosc A; Greffier A
    Transfus Clin Biol; 2003 Oct; 10(5):353-62. PubMed ID: 14572551
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Seventeen years of haemovigilance in France: assessment and outlook].
    Carlier M; Vo Mai MP; Fauveau L; Ounnoughene N; Sandid I; Renaudier P
    Transfus Clin Biol; 2011 Apr; 18(2):140-50. PubMed ID: 21474356
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Haemovigilance in 2013.
    Roberts DJ
    Transfus Med; 2013 Aug; 23(4):215-6. PubMed ID: 23865393
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.